Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03072550 · ClinicalTrials.gov registry record · NA
Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)
A NA study of Onychomycosis Due to Trichophyton Rubrum and Onychomycosis Due to Trichophyton Mentagrophytes, sponsored by DeviceFarm.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT03072550: Completed NA study of Onychomycosis Due to Trichophyton Rubrum and Onychomycosis Due to Trichophyton Mentagrophytes, sponsored by DeviceFarm.
NCT03072550 is a NA study of Onychomycosis Due to Trichophyton Rubrum and Onychomycosis Due to Trichophyton Mentagrophytes that has completed, run by DeviceFarm. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03072550, a NA study of Onychomycosis Due to Trichophyton Rubrum and Onychomycosis Due to Trichophyton Mentagrophytes, has completed, sponsored by DeviceFarm.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
Early feasibility study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.
Primary Outcome
mycological cure defined as two consecutive negative cultures per FDA guideline
Conditions Studied
Interventions
- DEVICE RenewalNail™ Plasma Treatment System
Study Locations (2)
California
- Center for Dermatology Clinical Research, Inc. - Fremont
- Center For Clinical Research Inc. - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-06-30 |
| Phase | NA |
What the finished NCT03072550 record still lists
NCT03072550 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Onychomycosis Due to Trichophyton Rubrum appearing as the primary indexed condition, and to 1 intervention - of which RenewalNail™ Plasma Treatment System is the first listed.
NCT03072550 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03072550 about?
NCT03072550 is a clinical study titled "Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)". Early feasibility study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.
What is the current status of trial NCT03072550?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2017-03-01. Estimated completion is 2018-06-30.
What conditions does trial NCT03072550 study?
This clinical trial studies the following conditions: Onychomycosis Due to Trichophyton Rubrum, Onychomycosis Due to Trichophyton Mentagrophytes.
What interventions are being tested in trial NCT03072550?
The interventions under investigation include: RenewalNail™ Plasma Treatment System (DEVICE).
Who is sponsoring clinical trial NCT03072550?
This trial is sponsored by DeviceFarm, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03072550 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03072550's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI